A new paper by Zhang et al. (Scientific Reports, 2025) provides the most comprehensive multi-omics analysis to date of TOP2A, revealing that this key nuclear enzyme is overexpressed across nearly all solid tumours and drives genomic instability, poor prognosis, and immune evasion. The authors conclude that TOP2A represents a pan-cancer oncogenic dependency and a promising target for precision therapy.

These findings directly support OncoTherics’ development of OCT1002, a next generation unidirectional Hypoxia-Activated Prodrug (uHAP) that releases a potent TOP2A poison selectively within hypoxic tumour cells. By targeting the very regions where conventional TOP2A inhibitors fail, OCT1002 exemplifies the next generation of precision chemotherapeutics designed to exploit tumour biology rather than harm normal tissue.